Diabetes, Metabolic Syndrome and Obesity (Dec 2019)
Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
Abstract
Caterina Lanna,* Gaia Maria Cesaroni,* Sara Mazzilli, Luca Bianchi, Elena Campione Dermatologic Unit, University of Rome Tor Vergata, Rome, Italy*These authors contributed equally to this workCorrespondence: Caterina LannaDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 81, Rome 00133, ItalyEmail [email protected]: Psoriasis is a common inflammatory skin condition frequently associated with cardiometabolic diseases such as diabetes. Indeed, the state of systemic inflammation typical of psoriasis leads to an increase in the level of IL-1, IL-6 and TNF-alpha which may cause a reduced sensitivity to insulin and, ultimately, can lead to type 2 diabetes mellitus. Particularly, the derangement of PDE4-cAMP signaling has a critical role in disordered glucose and lipid metabolism. Apremilast, as a selective inhibitor of PDE4-cAMP signalling, represents an innovative therapeutic strategy for psoriasis. Here, we report a case of a patient affected by psoriasis and diabetes, who – after using Apremilast – improved his glucose metabolism as well as his need of anti-diabetic drugs and his psoriasis. This suggests that, in addition to its role against psoriasis, Apremilast may even act as a metabolic modulator.Keywords: psoriasis, diabetes, PDE4-inhibitor
